Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going?

Author： Yamamoto Norio Tsuchiya Hiroyuki

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.16, 2013-11, pp. : 2183-2193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Insulin-like growth factor 1 receptor inhibitors: Where do we come from? What are we? Where are we going?

By Chmielowski Bartosz

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2384-2387

Blackwell Publishing

Access to resources Recommend Favorite

Personalized medicine in oncology: where have we come from and where are we going?

By André Fabrice Ciccolini Joseph Spano Jean-Philippe Penault-Llorca Frédérique Mounier Nicolas Freyer Gilles Blay Jean-Yves Milano Gérard

Pharmacogenomics, Vol. 14, Iss. 8, 2013-06 ,pp. : 931-939

Future Medicine

Access to resources Recommend Favorite

What should a Journal really be about? Where the JPPR came from, and Where it is going Next?

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 2, 2013-06 ,pp. : 93-94

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tuberculosis: where are we going?

By Thwaites Guy

Clinical Medicine, Vol. 6, Iss. 6, 2006-12 ,pp. : 523-525

Royal College Of Physicians

Access to resources Recommend Favorite

Pharmacogenetics in clinical practice: how far have we come and where are we going?

By Johnson Julie A

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 835-843

Future Medicine

Access to resources Recommend Favorite